Comment_老虎社区_美港股上老虎

2021-05-24

Comment

Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)<blockquote>为什么 Cathie Wood 看好 Iovance Biotherapeutics (IOVA)</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":131182629,"tweetId":"131182629","gmtCreate":1621835965361,"gmtModify":1634186202199,"author":{"id":3581744038722274,"idStr":"3581744038722274","authorId":3581744038722274,"authorIdStr":"3581744038722274","name":"clementboey","avatar":"https://static.tigerbbs.com/6f9db2e9f6ccd52532313cb1f8de13f4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Comment</body></html>","htmlText":"<html><head></head><body>Comment</body></html>","text":"Comment","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/131182629","repostId":1185350425,"repostType":4,"repost":{"id":"1185350425","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1621835821,"share":"https://www.laohunote.com/m/news/1185350425?lang=zh_CN&edition=full","pubTime":"2021-05-24 13:57","market":"us","language":"en","title":"Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)<blockquote>为什么 Cathie Wood 看好 Iovance Biotherapeutics (IOVA)</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1185350425","media":"Benzinga Earnings","summary":"Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherape","content":"Cathie Wood-led Ark Investment Management is betting that despite recent setbacks&nbsp;Iovance Biotherapeutics Inc&nbsp;IOVA 3.73%&nbsp;will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunotherapy.<blockquote>凯西·伍德 (Cathie Wood) 领导的方舟投资管理公司 (Ark Investment Management) 押注，尽管最近遭遇挫折Iovance 生物治疗公司IOVA 3.73% 将受益于其引人注目的肿瘤浸润性淋巴细胞 (TIL) 免疫疗法。</blockquote>What Happened:&nbsp;IOVA shares have declined 32% since Tuesday after the California-based&nbsp;biotech startup&nbsp;delayedits Biologics License Application (BLA) until the first half of 2022 because of FDA feedback on its potency tests.<blockquote>发生了什么：由于 FDA 对其效力测试的反馈，总部位于加州的生物技术初创公司将生物制剂许可证申请 (BLA) 推迟至 2022 年上半年，爱荷华州股价自周二以来已下跌 32%。</blockquote>The delay in the program is attributed to the FDA’s second request for additional data regarding potency assays, which are a series of tests that prove the company can consistently manufacture the product in question.<blockquote>该计划的延迟是由于美国食品和药物管理局第二次要求提供有关效力检测的更多数据，效力检测是一系列证明公司能够持续生产相关产品的测试。</blockquote>Soon after, IOVA announced CEO Maria Fardis is leaving the company after five years in the role and that General Counsel Frederick Vogt would be stepping in as interim CEO.&nbsp;Shares fell 39% on Wednesday after the announcement.<blockquote>不久之后，爱荷华州宣布首席执行官玛丽亚·法迪斯（Maria Fardis）将在担任该职位五年后离开公司，总法律顾问弗雷德里克·沃格特（Frederick Vogt）将接任临时首席执行官一职。消息公布后，周三股价下跌 39%。</blockquote>The New York-based investment firm started piling up shares in the company last week and holds 18.26 million IOVA shares, worth about $450.64 million, according to Ark’s data as of Friday’s trade.<blockquote>根据 Ark 截至周五交易的数据，这家总部位于纽约的投资公司上周开始增持该公司股票，持有 1826 万股 IOVA 股票，价值约 4.5064 亿美元。</blockquote>The&nbsp;Ark Genomic Revolution&nbsp;ETF (BATS:ARKG) and theArk Innovation ETF&nbsp;ARKK 0.75%&nbsp;carry the stake in IOVA.<blockquote>这个方舟基因组革命ETF (BATS:ARKG) 和方舟创新ETFARKK 0.75% 持有爱荷华州的股份。</blockquote>“We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set,” the Cathie Wood-led firm said in a note to investors.<blockquote>“凯西-伍德（Cathie Wood）领导的公司在给投资者的一份报告中说：”我们相信，Iovance 的 TIL 将继续成为市场上最引人注目的实体瘤疗法，Iovance 拥有最强大的 TIL 数据集。</blockquote>“Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.”<blockquote>“此外，在我们看来，Iovance 正在开创 FDA 监管程序的先河，其治疗黑色素瘤的 TIL 疗法很可能会获得 FDA 的批准，黑色素瘤是一种非常难以治疗的疾病，需求尚未得到满足。”</blockquote>Price Action:&nbsp;IOVA shares closed 3.73% lower at $18.05 on Friday.<blockquote>价格行为：爱荷华州股价周五收盘下跌 3.73%，至 18.05 美元。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)<blockquote>为什么 Cathie Wood 看好 Iovance Biotherapeutics (IOVA)</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)<blockquote>为什么 Cathie Wood 看好 Iovance Biotherapeutics (IOVA)</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nBenzinga Earnings \n2021-05-24 13:57\n</div>\n</div>\n</h4>\n</header>\n<article>\nCathie Wood-led Ark Investment Management is betting that despite recent setbacks&nbsp;Iovance Biotherapeutics Inc&nbsp;IOVA 3.73%&nbsp;will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunotherapy.<blockquote>凯西·伍德 (Cathie Wood) 领导的方舟投资管理公司 (Ark Investment Management) 押注，尽管最近遭遇挫折Iovance 生物治疗公司IOVA 3.73% 将受益于其引人注目的肿瘤浸润性淋巴细胞 (TIL) 免疫疗法。</blockquote>What Happened:&nbsp;IOVA shares have declined 32% since Tuesday after the California-based&nbsp;biotech startup&nbsp;delayedits Biologics License Application (BLA) until the first half of 2022 because of FDA feedback on its potency tests.<blockquote>发生了什么：由于 FDA 对其效力测试的反馈，总部位于加州的生物技术初创公司将生物制剂许可证申请 (BLA) 推迟至 2022 年上半年，爱荷华州股价自周二以来已下跌 32%。</blockquote>The delay in the program is attributed to the FDA’s second request for additional data regarding potency assays, which are a series of tests that prove the company can consistently manufacture the product in question.<blockquote>该计划的延迟是由于美国食品和药物管理局第二次要求提供有关效力检测的更多数据，效力检测是一系列证明公司能够持续生产相关产品的测试。</blockquote>Soon after, IOVA announced CEO Maria Fardis is leaving the company after five years in the role and that General Counsel Frederick Vogt would be stepping in as interim CEO.&nbsp;Shares fell 39% on Wednesday after the announcement.<blockquote>不久之后，爱荷华州宣布首席执行官玛丽亚·法迪斯（Maria Fardis）将在担任该职位五年后离开公司，总法律顾问弗雷德里克·沃格特（Frederick Vogt）将接任临时首席执行官一职。消息公布后，周三股价下跌 39%。</blockquote>The New York-based investment firm started piling up shares in the company last week and holds 18.26 million IOVA shares, worth about $450.64 million, according to Ark’s data as of Friday’s trade.<blockquote>根据 Ark 截至周五交易的数据，这家总部位于纽约的投资公司上周开始增持该公司股票，持有 1826 万股 IOVA 股票，价值约 4.5064 亿美元。</blockquote>The&nbsp;Ark Genomic Revolution&nbsp;ETF (BATS:ARKG) and theArk Innovation ETF&nbsp;ARKK 0.75%&nbsp;carry the stake in IOVA.<blockquote>这个方舟基因组革命ETF (BATS:ARKG) 和方舟创新ETFARKK 0.75% 持有爱荷华州的股份。</blockquote>“We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set,” the Cathie Wood-led firm said in a note to investors.<blockquote>“凯西-伍德（Cathie Wood）领导的公司在给投资者的一份报告中说：”我们相信，Iovance 的 TIL 将继续成为市场上最引人注目的实体瘤疗法，Iovance 拥有最强大的 TIL 数据集。</blockquote>“Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.”<blockquote>“此外，在我们看来，Iovance 正在开创 FDA 监管程序的先河，其治疗黑色素瘤的 TIL 疗法很可能会获得 FDA 的批准，黑色素瘤是一种非常难以治疗的疾病，需求尚未得到满足。”</blockquote>Price Action:&nbsp;IOVA shares closed 3.73% lower at $18.05 on Friday.<blockquote>价格行为：爱荷华州股价周五收盘下跌 3.73%，至 18.05 美元。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc.","ARKG":"ARK Genomic Revolution ETF","ARKK":"ARK Innovation ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185350425","content_text":"Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc IOVA 3.73% will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunotherapy.What Happened: IOVA shares have declined 32% since Tuesday after the California-based biotech startup delayedits Biologics License Application (BLA) until the first half of 2022 because of FDA feedback on its potency tests.The delay in the program is attributed to the FDA’s second request for additional data regarding potency assays, which are a series of tests that prove the company can consistently manufacture the product in question.Soon after, IOVA announced CEO Maria Fardis is leaving the company after five years in the role and that General Counsel Frederick Vogt would be stepping in as interim CEO. Shares fell 39% on Wednesday after the announcement.The New York-based investment firm started piling up shares in the company last week and holds 18.26 million IOVA shares, worth about $450.64 million, according to Ark’s data as of Friday’s trade.The Ark Genomic Revolution ETF (BATS:ARKG) and theArk Innovation ETF ARKK 0.75% carry the stake in IOVA.“We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set,” the Cathie Wood-led firm said in a note to investors.“Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.”Price Action: IOVA shares closed 3.73% lower at $18.05 on Friday.","news_type":1,"symbols_score_info":{"ARKG":0.9,"IOVA":0.9,"ARKK":0.9}},"isVote":1,"tweetType":1,"viewCount":1034,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/131182629"}